Results 151 to 160 of about 1,759 (167)

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

Expert Opinion on Drug Metabolism & Toxicology, 2022
CYP2D6 contributes to the metabolism of approximately 20-25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity. Moreover, there are commonly used drugs that potently inhibit the CYP2D6, thus causing 'phenoconversion' which can convert the genotypic normal metabolizer into
Noor A, Nahid, Julie A, Johnson
openaire   +2 more sources

The theoretical problems of “prodrome” and “phenoconversion” in neurodegeneration

2023
The recognition of and approach to prodromal symptoms, those which manifest before a diagnosis can be ascertained at the bedside, are of increasing interest in neurodegenerative research. A prodrome is conceived of as an early window into a disease, a critical time when putative disease-modifying interventions may be best suited for examination ...
Andrea, Sturchio, Alberto J, Espay
openaire   +2 more sources

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial

Clinical Pharmacology & Therapeutics, 2021
CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by concomitant drugs, which can lead to a clinical phenotype that is different from the genotype‐based phenotype, a process referred to as phenoconversion. Phenoconversion is highly
D. Max Smith, D. Max Smith, John T. Houder, Amanda R. Elsey, Cameron D. Thomas, Kristin Wiisanen, Emily J. Cicali, Larisa H. Cavallari, Julie A. Johnson, Kelsey J. Cook, Kelsey J. Cook, Amanda L. Elchynski   +11 more
openaire   +3 more sources

Phenocopy and Phenoconversion: Do they Complicate Association Studies?

Pharmacogenomics, 2012
Current pharmacogenetic focus on genotype A number of clinically relevant drug metabo­ lizing enzymes (DMEs) are expressed poly­ morphically in the population, giving rise to at least three distinct genotypes; extensive metabolizers (EMs), poor metabolizers (PMs) and intermediate metabolizers.
R R Shah, Robert L. Smith
openaire   +3 more sources

Mechanical regulation of myofibroblast phenoconversion and collagen contraction

Experimental Cell Research, 2019
Activated fibroblasts promote physiological wound repair following tissue injury. However, dysregulation of fibroblast activation contributes to the development of fibrosis by enhanced production and contraction of collagen-rich extracellular matrix.
Christopher A. McCulloch, Nuno M. Coelho, Boris Hinz   +2 more
openaire   +3 more sources

FoxO1 is required for high glucose-dependent cardiac fibroblasts into myofibroblast phenoconversion

Cellular Signalling, 2021
In the normal heart, cardiac fibroblasts (CFs) maintain extracellular matrix (ECM) homeostasis, whereas in pathological conditions, such as diabetes mellitus (DM), CFs converse into cardiac myofibroblasts (CMFs) and this CFs phenoconversion increase the synthesis and secretion of ECM proteins, promoting cardiac fibrosis and heart dysfunction.
Pablo Aránguiz, Raúl Vivar, Claudio Humeres, Mabel Catalán, Christopher Reyes, Alejandra Contreras, Fabiola González, Guillermo Díaz-Araya, Renatto Anfossi, Simone Cárdenas   +9 more
openaire   +3 more sources

I01 Unawareness of motor phenoconversion in huntington disease

Journal of Neurology, Neurosurgery & Psychiatry, 2012
Background Unawareness of disease manifestations in neurodegenerative diseases has been defined by Flashman et al 2002 as “pathological unawareness of a neurological or functional deficit” and by Antoine et al 2004 as “the discrepancy between the patient9s self report and the report of a natural caregiver or the clinical rating of a health ...
K Radford, Eric A. Epping, Jane Griffith, Jeffrey D. Long, David G. Gunn, Elizabeth McCusker, James A. Mills, J.S. Paulsen, Clement T. Loy, Clement T. Loy   +9 more
openaire   +2 more sources